These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36849795)

  • 1. Spherical PEG/SiO
    Razzaghi S; Vafaee M; Kharazian B; Nasrollahpour M
    Sci Rep; 2023 Feb; 13(1):3323. PubMed ID: 36849795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy.
    Colombatto P; Civitano L; Bizzarri R; Oliveri F; Choudhury S; Gieschke R; Bonino F; Brunetto MR;
    Antivir Ther; 2006; 11(2):197-212. PubMed ID: 16640101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients.
    Ingiliz P; Valantin MA; Thibault V; Duvivier C; Dominguez S; Katlama C; Poynard T; Benhamou Y
    Antivir Ther; 2008; 13(7):895-900. PubMed ID: 19043923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. pH-sensitive drug loading/releasing in amphiphilic copolymer PAE-PEG: integrating molecular dynamics and dissipative particle dynamics simulations.
    Luo Z; Jiang J
    J Control Release; 2012 Aug; 162(1):185-93. PubMed ID: 22743107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative.
    Sypsa VA; Mimidis K; Tassopoulos NC; Chrysagis D; Vassiliadis T; Moulakakis A; Raptopoulou M; Haida C; Hatzakis A
    Hepatology; 2005 Jul; 42(1):77-85. PubMed ID: 15962284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic antiviral effect of PEG-asparaginase (ONCASPAR), with protease inhibitor alone and in combination with RT inhibitors against HIV-1 infected T-cells: a model of HIV-1-induced T-cell lymphoma.
    Avramis VI; Kwock R; Avramis IA; Cohen LJ; Inderlied C
    In Vivo; 2001; 15(1):1-9. PubMed ID: 11286117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of HBsAg and HBV-DNA during therapy with peginterferon alpha-2b plus lamivudine and peginterferon alpha-2b alone in a German chronic hepatitis B cohort.
    Wiegand J; Brosteanu O; Kullig U; Wiese M; Berr F; Maier M; Tillmann HL; Schiefke I
    Z Gastroenterol; 2011 Nov; 49(11):1463-9. PubMed ID: 22069045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erratum: Preparation of Poly(pentafluorophenyl acrylate) Functionalized SiO2 Beads for Protein Purification.
    J Vis Exp; 2019 Apr; (146):. PubMed ID: 31038480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lamivudine (3TC) approved for combination use with AZT.
    James JS
    AIDS Treat News; 1995 Dec; (no 236):1-5. PubMed ID: 11363049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Semi-mechanistic Model to Characterize the Long-Term Dynamics of Hepatitis B Virus Markers During Treatment With Lamivudine and Pegylated Interferon.
    El Messaoudi S; Lemenuel-Diot A; Gonçalves A; Guedj J
    Clin Pharmacol Ther; 2023 Feb; 113(2):390-400. PubMed ID: 36408671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B.
    ter Borg MJ; Hansen BE; Herrmann E; Zeuzem S; Cakaloglu Y; Karayalcin S; Flisiak R; van' t Veen A; de Man RA; Schalm SW; Janssen HL; Haagmans BL;
    Antivir Ther; 2007; 12(8):1285-94. PubMed ID: 18240868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative evaluation of L-Fd4C and related nucleoside analogs as promising antiviral agents.
    Chen SH
    Curr Med Chem; 2002 May; 9(9):899-912. PubMed ID: 11966452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B].
    Ji YJ; Li FF; Ren WH; Zhu YH; Qin CY
    Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):335-9. PubMed ID: 24025132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PEGylated graphene oxide-capped gold nanorods/silica nanoparticles as multifunctional drug delivery platform with enhanced near-infrared responsiveness.
    Qi Z; Shi J; Zhang Z; Cao Y; Li J; Cao S
    Mater Sci Eng C Mater Biol Appl; 2019 Nov; 104():109889. PubMed ID: 31499943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicology and Carcinogenesis Studies of Mixtures of 3'-Azido-3'-Deoxythymidine (AZT), Lamivudine (3TC), and Nevirapine (NVP) (CAS Nos. 30516-87-1, 134678-17-4, 129618-40-2) in Genetically Modified C3B6.129F1-Trp53(tm1Brd) N12 Haploinsufficient Mice (in utero and postnatal gavage studies).
    National Toxicology Program
    Natl Toxicol Program Genet Modif Model Rep; 2013 Oct; (16):1-236. PubMed ID: 24503698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preformulation studies of novel 5'-O-carbonates of lamivudine with biological activity: solubility and stability assays.
    Gualdesi MS; Ravetti S; Raviolo MA; Briñón MC
    Drug Dev Ind Pharm; 2014 Sep; 40(9):1246-52. PubMed ID: 23855736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antiviral effect of lamivudine on HIV-1 targeting MT2 cells influenced by morphine].
    Liang BY; Zhuang DM; Jiang JJ; Liu SY; Su QJ; Li JY; Liang H
    Zhonghua Liu Xing Bing Xue Za Zhi; 2011 Jul; 32(7):705-8. PubMed ID: 21933545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy of Peg-Interferon/Ribavirin with and without Lamivudine therapy for HBeAg-positive hepatitis B and C dual infection.
    Yeh ML; Hsieh MY; Huang CI; Huang CF; Hsieh MH; Huang JF; Dai CY; Chuang WL; Yu ML
    J Gastroenterol Hepatol; 2016 Apr; 31(4):835-41. PubMed ID: 26478984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.